Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy

Trial Profile

Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Gefitinib (Primary) ; Docetaxel
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2014 Status changed from active, no longer recruiting to discontinued, as per M.D. Anderson Cancer Center record.
    • 16 Sep 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 13 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top